Urology PR Firms and industry professionals are undergoing a period of swift transformation, driven by research breakthroughs, technology advancements and revamped standards of care. The changes in the urology field are improving clinical accuracy while also increasing education surrounding comfort, accessibility and effective care. The news roundup below highlights the rapid pace of innovation in urology and the progress establishing these practices.
AI Is Changing How Urologic Conditions Are Diagnosed and Treated – Renal & Urology News
On June 18, 2025, the European Association of Urology (EAU) announced it is supporting the European Strategy for AI in Science and plans to work with urologists as AI platforms continue to transform urology. Currently, the EAU maintains a comprehensive platform that uses the power of big data, AI, and real-world evidence (RWE) to improve patient care across all urological conditions. It is called The UroEvidenceHub. It aims to bridge the gap between clinical practice guidelines and individual patient characteristics. The UroEvidenceHub integrates data from various sources, including clinical trials, EHRs, and patient-reported outcomes (PROMS).
The benefits of AI in urology also include earlier and more accurate diagnosis, improved resource allocation, and potentially better outcomes. However, there are significant limitations. Many models are developed and validated in narrowly defined populations, raising concerns about generalizability. Further, access to these urologic tools may be uneven, favoring institutions that invest in digital infrastructure and high-performance computing. “Additionally, the ‘black box’ nature of many deep learning models makes it difficult to investigate erroneous or hallucinated outputs which poses challenges for clinical trust, interpretability, and liability,” said Dr Nayan. “As AI becomes more embedded in clinical workflows, there is a risk of overreliance on technology at the expense of clinical judgment.”
First Bladder Transplant Offers New Hope for Patients With Terminal Benign Bladders – Renal & Urology News
On May 4, 2025, the first bladder transplant in a living person was successfully performed at the University of California Los Angeles (UCLA) Health. A team of urologic transplant surgeons from UCLA Health and Keck Medicine at the University of Southern California (USC) in Los Angeles reported this ground-breaking procedure. The patient had lost most of his bladder during a tumor removal. Next, renal cancer claimed both of his kidneys. He was on dialysis for 7 years. The patient underwent a dual kidney-bladder transplant.
For the first bladder transplant in a living patient, the team retrieved and transplanted an entire vascular composite bladder allograft (VCBA) after first transplanting a donated kidney. The new kidney was then connected to the new bladder using the innovated techniques. “This highly complex bladder-kidney transplant surgery took over 8 hours to complete. The inherent challenges of transplantation aside, the principal technical complexity stems from the donor cystectomy, with its complex vascular anatomy and numerous deep pelvic blood vessels. This necessitates high-precision surgery to retrieve intact the vesical pedicles, vascular arcade, and meso-vesicum, en bloc with the bladder,” Dr Gill said.
Making urology care a positive experience for women – UCI Health
Pain and fear of pain make urology care an uncomfortable experience for many women. This can impede their access to needed care for urinary incontinence or other urological problems.
The good news is that the American College of Obstetricians and Gynecologists (ACOG) has recently released pain management guidance for in-office procedures. At its core is the recommendation to provide comprehensive counseling so that patients are aware of their options and empowered to choose what it best for them.
Dr. Felicia Lane, a urogynecologist at UCI Health, spoke with Medscape about limiting invasive testing as much as possible.
FDA clears image-guided navigation platform for focal therapy in prostate cancer – Urology Times
The FDA has granted 510(k) clearance to an updated version of the Philips UroNav System, an advanced image-guided navigation platform designed to enhance the precision of minimally invasive therapy procedures in prostate cancer.1
The new advanced annotation workflow on the UroNav System is designed to work in tandem with DynaCAD Urology to support focal therapy planning, delivery, and review. DynaCAD Urology can be used to display prostate boundaries and targets defined by radiology, allowing urologists to edit prostate segmentation and add targets if needed. The resulting plan can then be used by the Philips UroNav System.2
Balancing nutrition and bladder health in eating disorder recovery – Urology Times
In this interview, Aleece Fosnight, MSPAS, PA-C, CSC-S, CSE, IF, MSCP, HAES, founder of the Fosnight Center for Sexual Health and medical advisor for Aeroflow Urology, emphasizes a careful, individualized approach to managing bladder and bowel symptoms in women with a history of disordered eating. She advises framing these changes as temporary “pauses” rather than restrictions to avoid triggering disordered eating behaviors. Reintroduction should progress from least to most irritating foods under the guidance of a nutritionist or dietitian, with attention to mental health.
UC Davis scholar’s prostate cancer research gets federal funding boost – UC Davis Health
The PCRP Early Investigator Research Award supports prostate cancer-focused research opportunities for individuals in the early stages of their careers under the guidance of one or more designated mentors. Ning’s research project is co-mentored by Gao and Department of Urologic Surgery Chair Marc Dall’Era.
The award allows early-career investigators to develop a research project, investigate a problem or question in prostate cancer research and advance their intellectual development as prostate cancer researchers.
New treatment eliminates bladder cancer in 82% of patients – Keck Medicine of USC
TAR-200 is a miniature, pretzel-shaped drug-device duo containing a chemotherapy drug, gemcitabine, which is inserted into the bladder through a catheter. Once inside the bladder, the TAR-200 slowly and consistently releases the gemcitabine into the organ for three weeks per treatment cycle.
Traditionally, gemcitabine has been delivered to the bladder as a liquid solution that only stays in the bladder for a few hours, which had limited effect destroying the cancer, said Daneshmand, who is also a member of the USC Norris Comprehensive Cancer Center.
The standard treatment for this type of bladder cancer is an immunotherapy drug, Bacillus Calmette-Guérin, which may be ineffective in a percentage of patients. All the patients in the clinical trial had been previously treated with this drug, but their cancer had returned.
Handheld test for urinary tract infections takes 30 min – Chemical & Engineering News
Urinary tract infections (UTIs) are the most common infection seen in US outpatient clinics, prompting around 10 million medical visits per year. Urine culture, which is painstakingly slow, remains the standard for diagnosis. Missed or delayed diagnosis can cause complications, and rising antibiotic resistance in many UTI-causing bacteria makes the condition even more dangerous.
The entire test—detecting the infection and gauging antibiotic resistance—could be done in around 30 min, a drastic improvement over conventional urine culture. The researchers validated the accuracy of the diagnostic on a small number of clinical samples, and all results agreed with culture tests.
Single-Dose Fosfomycin Found as Safe, Effective as Other Antibiotics for Uncomplicated UTIs – AJMC
Fosfomycin is a broad-spectrum antibiotic effective against both Gram-positive and Gram-negative bacteria, including drug-resistant organisms.2 Past evidence demonstrated that a single oral dose of fosfomycin is a potential treatment option for lower UTIs in both pregnant and nonpregnant women.1 Additionally, fosfomycin is considered more economically viable than many other primary UTI treatment alternatives.
Despite this, drug utilization studies have demonstrated significantly less use of fosfomycin compared with commonly used therapies, such as nitrofurantoin and fluoroquinolones. As a result, there is a lack of conclusive evidence for recommending single-dose fosfomycin as the first line of management for patients with uncomplicated UTIs.
Emerging biomarkers in bladder cancer: Translating molecular advances into precision oncology – ScienceDirect.com
Bladder cancer (BC) is among the most common malignancies of the urinary tract, showing significant clinical challenges, being heterogeneous, and affected by variable progression. Traditional diagnostic and therapeutic approaches often fail to account for the molecular and genetic diversity of the disease (Dwivedi et al., 2017). This limitation has driven a growing interest in precision medicine. To date, conventional therapeutic schemes are based on individual patient characteristics, including genetic or molecular markers, as well as environmental factors.
In recent years, the rapidly evolving scenario of molecular biomarkers, played a pivotal role in transforming the landscape of BC management (Tomiyama et al., 2024 Mar). These biomarkers aid both in early diagnosis and prognostic assessment and in guiding therapeutic decision-making. This review aims to explore the current advancements in emerging biomarkers for BC, highlighting their potential roles in precision medicine.
Does your healthcare, biotech or life sciences organization need the right coverage?
FischTank PR has extensive experience in the healthcare, health & wellness and biotech sectors. More specifically, we have honed our Urology PR media relations, and broader health media relations, for prominent health brands including Anthem Healthcare, Icahn School of Medicine at Mount Sinai and Aeroflow Urology, among many others.
If you’re interested in securing exposure for your urology PR initiative or campaign, or any healthcare initiative, reach out to us at [email protected].
***News roundup guest post from FischTank PR intern Abby Collins***
